PET Patterns, Biomarkers and Outcome in Burst SCS Treated FBSS Patients

N/AUnknownNCT03419312

Uppsala University12 enrolled

Overview

The primary aim of this study is to investigate cerebral mechanisms of burst stimulation in Failed Back Surgery Syndrome (FBSS) patients treated with Burst Spinal Cord Stimulation (SCS) for chronic back and leg pain. This study is a single center, prospective, blinded, randomized crossover trial with two 14 days treatment periods and two treatment arms (burst before sham stimulation or sham before burst stimulation).

Background and rationale: Tonic spinal cord stimulation for chronic primarily neuropathic pain har been used for over 50 years. Tonic stimulation in frequencies from 20 to 70 Hz produces analgesia and paresthesia in the targeted area. Burst stimulation, a novel spinal cord stimulation pattern, is an intermittent high frequency parenthesis-free therapy. This stimulation pattern consist of 5 spikes with an inter-spike frequency of 500 Hz, delivered at 40 Hz. Clinical effectiveness and noninferiority of Burst stimulation has been proved. A few studies suggest that Burst stimulation induce different activities in cerebral pathways, compared with tonic stimulation. Patient reported attention to pain assessed by the pain vigilance and awareness questionnaire (PVAQ) seems to differ between burst and tonic spinal cord stimulation. This trial is designed to investigate cerebral mechanisms of burst stimulation, using PET O15-water measured blood flow and tissue perfusion as a proxy for cerebral activity. Key events in study implementation: Study phase 1 * Study Inclusion and baseline visit. * Implantation of spinal cord stimulation system. Study phase 2: * Study visit 1(study day 0): Collection of Patient Reported Outcome Measurements (PROM) data, Randomization to study sequence, blood sampling, PET 0, programming of SCS-system. * Study visit 2 (study day 14): Blood sampling, PET 1, collection of PROM-data, SCS system switched off for washout. * Study visit 3 (study day 21): Collection of PROM-data, programming of SCS-system, blood sampling. * Study visit 4 (study day 35): Blood sampling, PET 2, collection of PROM-data, programming of SCS-system.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

Conditions

FBSS Pain, Intractable Low Back Pain Radicular; Neuropathic, Lumbar, Lumbosacral

Interventions

Proclaim™ Elite 5: Burst - Washout - ShamDEVICE

All implanted hardware manufactured by S:t Jude Medical/Abbot: Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106.

Proclaim™ Elite 5: Sham - Washout - BurstDEVICE

Eligibility

Sex: ALLMin age: 18 YearsMax age: 59 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Occurrence of chronic pain in the lumbosacral region, as well as unilateral or bilateral leg pain. 2. Prior lumbar surgery in medical history. 3. Diagnosed with neuropathic pain in the lower extremities and graded as probable neuropathic pain or definite neuropathic pain according International Association for the Study of Pain (IASP) criteria. 4. Patient report largely unchanged pain condition last 6 months. 5. Patient has undergone a 7 day SCS trial with epidural burst stimulation with the following results: 1. At least 75% coverage of the painful area of tonic stimulation before start of burst trial stimulation. 2. At least 50% reduction in pain intensity, measured via BPI, item 5 from baseline of trial to end of trial period. 6. The patient is ≥ 18 years of age and \< 60 years of age. 7. The patient must willingly participate in all parts of the study, as well as having the ability to complete the entire study plan. 8. Patient must certify that he / she understands the study plan, as well as voluntarily sign informed consent to participate in the study. 9. Must be able to sit still for a minimum of 45 minutes and be able to follow restrictions related to the PET survey. Exclusion Criteria: 1. The patient has other current pain conditions than back and leg pain after back surgery. 2. The patient is treated with opioids exceeding 80 milligrams of Morphine per day or is considered at risk for development of problematic opioid use. 3. The patient suffers from an untreated depression or anxiety. 4. The patient can not complete the study plan. 5. The patient is unable to read or write Swedish. 6. The patient is currently participates in another clinical trial. 7. A history of previous PET scan or other substantial radiation dose in the last 5 years. 8. The patients is suffering from claustrophobia. 9. Ongoing pregnancy or planned pregnancy during study time. 10. The patient has contraindications for arterial catheterization. 11. The patient is previously treated with spinal cord stimulation.

Locations (1)

Uppsala University Hospital, Uppsala University, Dept. of Surgical Sciences and Dept. of Medicinal Chemistry, Div. of Molecular Imaging.

Uppsala, Sweden

Outcomes

Primary Outcomes

Change in regional cerebral blood flow measured with 15O-water Positron Emission. Tomography (PET)

35 Volume of Interest (VOI) will be applied to each PET scan using the PVElab software. Cerebral blood flow (CBF) and perfusable tissue fraction (PTF) will be calculated for each VOI at each scan. Same tests will be done at voxel level with the Statistical Parameter Mapping Software (SPM12), to identify areas with changed CBF or PTF that do not correspond to VOI in the template.

Time frame: PET is performed at study day 0 (baseline), day 14 and day 35.

Secondary Outcomes

Semiquantitative assessment of protein levels associated with inflammation.

Level of normalized protein expression (NPX) in plasma, assessed by a multiplex proximity extension assay panel (Olink Bioscience, Uppsala, Sweden).

Time frame: Measured at day 0 (baseline), day 14, day 21 and day 35.

Back and leg pain

Measured using a 100mm Visual Analog Scale (VAS) for back and leg pain, respectively. Scale range: 0 mm indicates no pain (minimum), 100 mm indicates worst imaginable pain (maximum).

Time frame: Measured at visit day 0 (baseline), day 14 and day 35.

General pain

General pain measured by Brief Pain Inventory (BPI) item 3, 4, 5 and 6

Time frame: Measured at day 0 (baseline), day 14 and day 35.

Pain inference

Measured by BPI item 9A-9G

Time frame: Measured at day 0 (baseline), day 14 and day 35.

Disability

Disability measured by Oswestry Disability Index (ODI).

Time frame: Measured at day 0 (baseline), day 14 and day 35.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.